External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.
Authors Naree WarnnissornNonglak KanitsapPimjai NiparuckPaisarn BoonsakanPrapasri KulalertWasithep LimvorapitakLantarima BhoopatSupawee SaengboonPichika ChantrathammachartTeeraya PuavilaiSuporn ChuncharuneePublished in: Hematology (Amsterdam, Netherlands) (2022)
NCCN-IPI is the best prognostic index compared to IPI and R-IPI in prior studies. However, the prognostic model for DLBCL patients treated with R-CHOP requires updating or integrating biomarkers to improve discrimination to the acceptable level (c-index 0.7).